Chemical Formula: C16H25NO4

Chemical Formula C16H25NO4

Found 49 metabolite its formula value is C16H25NO4

Esmolol

methyl 3-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)propanoate

C16H25NO4 (295.178349)


Esmolol (trade name Brevibloc) is a cardioselective beta1 receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilising activity at therapeutic dosages. Esmolol decreases the force and rate of heart contractions by blocking beta-adrenergic receptors of the sympathetic nervous system, which are found in the heart and other organs of the body. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists

   
   

(2E,4E,7E)-Nona-2,4,7-trienoylcarnitine

3-(Nona-2,4,7-trienoyloxy)-4-(trimethylazaniumyl)butanoic acid

C16H25NO4 (295.178349)


(2E,4E,7E)-nona-2,4,7-trienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,4E,7E)-nona-2,4,7-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,4E,7E)-nona-2,4,7-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,4E,7E)-nona-2,4,7-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Nona-2,4,6-trienoylcarnitine

3-(Nona-2,4,6-trienoyloxy)-4-(trimethylazaniumyl)butanoic acid

C16H25NO4 (295.178349)


Nona-2,4,6-trienoylcarnitine is an acylcarnitine. More specifically, it is an nona-2,4,6-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. nona-2,4,6-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nona-2,4,6-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Nona-3,5,7-trienoylcarnitine

3-(Nona-3,5,7-trienoyloxy)-4-(trimethylazaniumyl)butanoic acid

C16H25NO4 (295.178349)


Nona-3,5,7-trienoylcarnitine is an acylcarnitine. More specifically, it is an nona-3,5,7-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. nona-3,5,7-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nona-3,5,7-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Lycoposerramine F

Lycoposerramine F

C16H25NO4 (295.178349)


   
   
   
   

(2E,7E,9E)-6-hydroxy-N-(2-hydroxy-2-methylpropyl)-11-oxo-2,7,9-dodecatrienamide|(6RS)-(2E,7E,9E)-6-hydroxy-N-(2-hydroxy-2-methylpropyl)-11-oxo-2,7,9-dodecatrienamide|ZP-amide A

(2E,7E,9E)-6-hydroxy-N-(2-hydroxy-2-methylpropyl)-11-oxo-2,7,9-dodecatrienamide|(6RS)-(2E,7E,9E)-6-hydroxy-N-(2-hydroxy-2-methylpropyl)-11-oxo-2,7,9-dodecatrienamide|ZP-amide A

C16H25NO4 (295.178349)


   

6beta-Propanoyloxy-3alpha-tigloyloxytropane

6beta-Propanoyloxy-3alpha-tigloyloxytropane

C16H25NO4 (295.178349)


   

(11RS)-(2E,7E,9E)-11-hydroxy-N-(2-hydroxy-2-methylpropyl)-6-oxo-2,7,9-dodecatrienamide|ZP-amide B

(11RS)-(2E,7E,9E)-11-hydroxy-N-(2-hydroxy-2-methylpropyl)-6-oxo-2,7,9-dodecatrienamide|ZP-amide B

C16H25NO4 (295.178349)


   

oxystemokerrilactone

oxystemokerrilactone

C16H25NO4 (295.178349)


   

4alpha,8beta,12beta-trihydroxylycopodine

4alpha,8beta,12beta-trihydroxylycopodine

C16H25NO4 (295.178349)


   

ESMOLOL

ESMOLOL

C16H25NO4 (295.178349)


C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists

   

5-cis-3-oxo-C12-HSL

N-(3-oxo-5Z-dodecenoyl)-homoserine lactone

C16H25NO4 (295.178349)


   

Floredil

4-[2-(3,5-Diethoxyphenoxy)ethyl]morpholine

C16H25NO4 (295.178349)


C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent

   

N-Phenylaza-15-crown 5-Ether

N-Phenylaza-15-crown 5-Ether

C16H25NO4 (295.178349)


   
   

Boc-O-Benzyl-D-threoninol

Boc-O-Benzyl-D-threoninol

C16H25NO4 (295.178349)


   

Di-(tert-butyl) 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate

Di-(tert-butyl) 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate

C16H25NO4 (295.178349)


   
   

(S)-ETHYL 1-(2-CYCLOHEXYL-2-OXOACETYL)PIPERIDINE-2-CARBOXYLATE

(S)-ETHYL 1-(2-CYCLOHEXYL-2-OXOACETYL)PIPERIDINE-2-CARBOXYLATE

C16H25NO4 (295.178349)


   

1-(2,6-Dimethyl-4-morpholinyl)-3-(4-methoxyphenoxy)-2-propanol

1-(2,6-Dimethyl-4-morpholinyl)-3-(4-methoxyphenoxy)-2-propanol

C16H25NO4 (295.178349)


   
   
   

Nona-2,4,6-trienoylcarnitine

Nona-2,4,6-trienoylcarnitine

C16H25NO4 (295.178349)


   

Nona-3,5,7-trienoylcarnitine

Nona-3,5,7-trienoylcarnitine

C16H25NO4 (295.178349)


   

(2E,4E,7E)-Nona-2,4,7-trienoylcarnitine

(2E,4E,7E)-Nona-2,4,7-trienoylcarnitine

C16H25NO4 (295.178349)


   

(1r,6r,9s,10r,11r,12s)-6-[(1s)-1-hydroxypropyl]-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-one

(1r,6r,9s,10r,11r,12s)-6-[(1s)-1-hydroxypropyl]-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-one

C16H25NO4 (295.178349)


   

3-(1-hydroxy-2-methyloct-6-en-1-ylidene)-5-(1-hydroxyethyl)-1-methylpyrrolidine-2,4-dione

3-(1-hydroxy-2-methyloct-6-en-1-ylidene)-5-(1-hydroxyethyl)-1-methylpyrrolidine-2,4-dione

C16H25NO4 (295.178349)


   

(1s,2s,4s,4as,11ar,13as)-1,4-dihydroxy-2-methyl-12-oxo-dodecahydroindeno[3a,3-i]indolizin-8-ium-8-olate

(1s,2s,4s,4as,11ar,13as)-1,4-dihydroxy-2-methyl-12-oxo-dodecahydroindeno[3a,3-i]indolizin-8-ium-8-olate

C16H25NO4 (295.178349)


   

(2e,6r,7e,9e)-6-hydroxy-n-(2-hydroxy-2-methylpropyl)-11-oxododeca-2,7,9-trienimidic acid

(2e,6r,7e,9e)-6-hydroxy-n-(2-hydroxy-2-methylpropyl)-11-oxododeca-2,7,9-trienimidic acid

C16H25NO4 (295.178349)


   

11-hydroxy-n-(2-hydroxy-2-methylpropyl)-6-oxododeca-2,7,9-trienimidic acid

11-hydroxy-n-(2-hydroxy-2-methylpropyl)-6-oxododeca-2,7,9-trienimidic acid

C16H25NO4 (295.178349)


   

(3z,5r)-3-[(2s,6e)-1-hydroxy-2-methyloct-6-en-1-ylidene]-5-[(1r)-1-hydroxyethyl]-1-methylpyrrolidine-2,4-dione

(3z,5r)-3-[(2s,6e)-1-hydroxy-2-methyloct-6-en-1-ylidene]-5-[(1r)-1-hydroxyethyl]-1-methylpyrrolidine-2,4-dione

C16H25NO4 (295.178349)


   

(1r,2s,6r,10r,13s,15s)-2,10-dihydroxy-15-methyl-11-oxo-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadecan-6-ium-6-olate

(1r,2s,6r,10r,13s,15s)-2,10-dihydroxy-15-methyl-11-oxo-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadecan-6-ium-6-olate

C16H25NO4 (295.178349)


   

1,4-dihydroxy-3-(3-hydroxy-2,3,5,7-tetramethylcycloheptyl)pyridin-2-one

1,4-dihydroxy-3-(3-hydroxy-2,3,5,7-tetramethylcycloheptyl)pyridin-2-one

C16H25NO4 (295.178349)


   

(2e,7e,9e,11r)-11-hydroxy-n-(2-hydroxy-2-methylpropyl)-6-oxododeca-2,7,9-trienimidic acid

(2e,7e,9e,11r)-11-hydroxy-n-(2-hydroxy-2-methylpropyl)-6-oxododeca-2,7,9-trienimidic acid

C16H25NO4 (295.178349)


   

(1r,2s,10r,13s,15s)-2,10-dihydroxy-15-methyl-11-oxo-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadecan-6-ium-6-olate

(1r,2s,10r,13s,15s)-2,10-dihydroxy-15-methyl-11-oxo-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadecan-6-ium-6-olate

C16H25NO4 (295.178349)


   

8-methyl-6-(propanoyloxy)-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

8-methyl-6-(propanoyloxy)-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

C16H25NO4 (295.178349)


   

(3z,5r)-3-[(6e)-1-hydroxy-2-methyloct-6-en-1-ylidene]-5-(1-hydroxyethyl)-1-methylpyrrolidine-2,4-dione

(3z,5r)-3-[(6e)-1-hydroxy-2-methyloct-6-en-1-ylidene]-5-(1-hydroxyethyl)-1-methylpyrrolidine-2,4-dione

C16H25NO4 (295.178349)


   

6-hydroxy-n-(2-hydroxy-2-methylpropyl)-11-oxododeca-2,7,9-trienimidic acid

6-hydroxy-n-(2-hydroxy-2-methylpropyl)-11-oxododeca-2,7,9-trienimidic acid

C16H25NO4 (295.178349)


   

(3z,5s)-3-[(2s,6e)-1-hydroxy-2-methyloct-6-en-1-ylidene]-5-[(1s)-1-hydroxyethyl]-1-methylpyrrolidine-2,4-dione

(3z,5s)-3-[(2s,6e)-1-hydroxy-2-methyloct-6-en-1-ylidene]-5-[(1s)-1-hydroxyethyl]-1-methylpyrrolidine-2,4-dione

C16H25NO4 (295.178349)


   

(1s,2s,4s,4as,8s,11ar,13as)-1,4-dihydroxy-2-methyl-12-oxo-dodecahydroindeno[3a,3-i]indolizin-8-ium-8-olate

(1s,2s,4s,4as,8s,11ar,13as)-1,4-dihydroxy-2-methyl-12-oxo-dodecahydroindeno[3a,3-i]indolizin-8-ium-8-olate

C16H25NO4 (295.178349)


   

1,4-dihydroxy-3-[(1r,2s,3s,5r,7s)-3-hydroxy-2,3,5,7-tetramethylcycloheptyl]pyridin-2-one

1,4-dihydroxy-3-[(1r,2s,3s,5r,7s)-3-hydroxy-2,3,5,7-tetramethylcycloheptyl]pyridin-2-one

C16H25NO4 (295.178349)


   

(3z,5s)-3-[(6e)-1-hydroxy-2-methyloct-6-en-1-ylidene]-5-(1-hydroxyethyl)-1-methylpyrrolidine-2,4-dione

(3z,5s)-3-[(6e)-1-hydroxy-2-methyloct-6-en-1-ylidene]-5-(1-hydroxyethyl)-1-methylpyrrolidine-2,4-dione

C16H25NO4 (295.178349)


   

(1r,2s,3s,9s,10r,13s,14s)-2,3-dihydroxy-14-propyl-11-oxa-5-azatetracyclo[7.4.1.1¹⁰,¹³.0⁵,¹⁴]pentadecan-12-one

(1r,2s,3s,9s,10r,13s,14s)-2,3-dihydroxy-14-propyl-11-oxa-5-azatetracyclo[7.4.1.1¹⁰,¹³.0⁵,¹⁴]pentadecan-12-one

C16H25NO4 (295.178349)


   

(1r,6r,9r,10r,11r,12s)-6-[(1r)-1-hydroxypropyl]-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-one

(1r,6r,9r,10r,11r,12s)-6-[(1r)-1-hydroxypropyl]-12-methyl-14,15-dioxa-5-azatetracyclo[7.5.1.0¹,¹¹.0⁵,¹⁰]pentadecan-13-one

C16H25NO4 (295.178349)